(Q27908387)

English

ERBB2 Amplification

genetic variant

OVEREXPRESSION
AMPLIFICATION

In more languages

Statements

Transcript Amplification

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/306

human chromosome 17

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/306

37856333

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/306

37884915

genomic assembly

Genome assembly GRCh37

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/306

biological variant of

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/306

positive therapeutic predictor for

determination method

CIViC evidence level B

CIViC 5-star trust rating

medical condition treated

Her2-receptor positive breast cancer

2 references

23 May 2022

https://civic.genome.wustl.edu/links/evidence/528

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

23 May 2022

https://civic.genome.wustl.edu/links/evidence/529

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

uterine corpus endometrial carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/886

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

Her2-receptor positive breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/887

A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

Her2-receptor positive breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/887

A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

Her2-receptor positive breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/887

A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

Her2-receptor positive breast cancer

2 references

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1010

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1011

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): ...

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

pancreatic adenocarcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/962

Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status

Trastuzumab / Lapatinib combination therapy

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1006

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

Trastuzumab / Lapatinib combination therapy

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

Her2-receptor positive breast cancer

3 references

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1007

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1009

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1439

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

Trastuzumab / Lapatinib combination therapy

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

Her2-receptor positive breast cancer

statement disputed by

Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1008

Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

Her2-receptor positive breast cancer

statement disputed by

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1012

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial

afatinib / Trastuzumab combination therapy

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

Her2-receptor positive breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1013

Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

non-small-cell lung carcinoma

statement disputed by

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1041

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

non-small-cell lung carcinoma

statement disputed by

Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1042

Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial

Trastuzumab / irinotecan combination therapy

determination method

CIViC evidence level C

CIViC 4-star trust rating

medical condition treated

lung small cell carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1044

Favorable response to trastuzumab plus irinotecan combination therapy in two patients with HER2-positive relapsed small-cell lung cancer

ado-trastuzumab emtansine

determination method

CIViC evidence level D

CIViC 4-star trust rating

medical condition treated

non-small-cell lung carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1050

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance

docetaxel trihydrate / Trastuzumab / Pertuzumab combination therapy

determination method

CIViC evidence level B

CIViC 5-star trust rating

medical condition treated

Her2-receptor positive breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1077

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

determination method

CIViC evidence level C

CIViC 4-star trust rating

medical condition treated

uterine corpus serous adenocarcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1097

Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

endometrial cancer

statement disputed by

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1098

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study

capecitabine / lapatinib combination therapy

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

Her2-receptor positive breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1132

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

capecitabine / Trastuzumab combination therapy

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

Her2-receptor positive breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1133

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

ado-trastuzumab emtansine

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

Her2-receptor positive breast cancer

3 references

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1159

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1160

Trastuzumab emtansine for HER2-positive advanced breast cancer

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1764

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

Her2-receptor positive breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1380

The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

Her2-receptor positive breast cancer

statement disputed by

The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1382

The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis

ado-trastuzumab emtansine

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

Her2-receptor positive breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1432

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

docetaxel trihydrate / Trastuzumab / Pertuzumab combination therapy

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

Her2-receptor positive breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1437

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

Trastuzumab / palbociclib combination therapy

determination method

CIViC evidence level D

CIViC 2-star trust rating

medical condition treated

Her2-receptor positive breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1561

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

determination method

CIViC evidence level C

CIViC 2-star trust rating

medical condition treated

scrotum Paget's disease

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1693

Metastatic Extramammary Paget's Disease of Scrotum Responds Completely to Single Agent Trastuzumab in a Hemodialysis Patient: Case Report, Molecular Profiling and Brief Review of the Literature.

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

non-small-cell lung carcinoma

statement disputed by

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1891

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

Pertuzumab / Trastuzumab combination therapy

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5981

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

Pertuzumab / Trastuzumab combination therapy

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

bladder carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5982

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

Pertuzumab / Trastuzumab combination therapy

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5983

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

Pertuzumab / Trastuzumab combination therapy

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

salivary gland carcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5984

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

Pertuzumab / Trastuzumab combination therapy

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

pancreatic cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5985

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

Pertuzumab / Trastuzumab combination therapy

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

statement disputed by

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/5986

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.

Trastuzumab / Lapatinib combination therapy

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1689

Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial

determination method

CIViC evidence level A

CIViC 4-star trust rating

medical condition treated

Her2-receptor positive breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1122

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

Pertuzumab / Trastuzumab combination therapy

determination method

CIViC evidence level C

CIViC 3-star trust rating

medical condition treated

cholangiocarcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/7638

Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma

Pertuzumab / Trastuzumab combination therapy

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/7302

Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

gastric adenocarcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1022

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

gastric adenocarcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1023

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study

determination method

CIViC evidence level A

CIViC 4-star trust rating

medical condition treated

gastric adenocarcinoma

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1499

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

Her2-receptor positive breast cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/761

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

determination method

CIViC evidence level D

CIViC 3-star trust rating

medical condition treated

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/2071

Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models

negative therapeutic predictor for

Cetuximab / capecitabine / Oxaliplatin combination therapy

determination method

CIViC evidence level B

CIViC 1-star trust rating

medical condition treated

colorectal cancer

statement disputed by

HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/895

HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab

determination method

CIViC evidence level C

CIViC 1-star trust rating

medical condition treated

adenocarcinoma of the lung

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1393

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

determination method

CIViC evidence level C

CIViC 1-star trust rating

medical condition treated

adenocarcinoma of the lung

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1393

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1688

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients

determination method

CIViC evidence level B

CIViC 2-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1688

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients

determination method

CIViC evidence level B

CIViC 3-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1993

HER2 Amplification and Cetuximab Efficacy in Patients With Metastatic Colorectal Cancer Harboring Wild-type RAS and BRAF.

determination method

CIViC evidence level B

CIViC 4-star trust rating

medical condition treated

colorectal cancer

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1687

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

negative prognostic predictor for

uterine corpus serous adenocarcinoma

determination method

CIViC evidence level B

CIViC 4-star trust rating

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/evidence/1096

Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer

Identifiers

CIViC variant ID

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/306

HGVS nomenclature

no value

1 reference

23 May 2022

https://civic.genome.wustl.edu/links/variants/306

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27908387&oldid=2014797557"